Pathogenetic and diagnostic role of osteoprotegerin in the combined course of osteoarthritis and obesity

Abstract

In recent years, it has been proven that the formation of OA can occur against the background of impaired bone metabolism. Bone remodeling is considered as a continuous complex process aimed at eliminating microdamages and updating the bone matrix. A key link in the regulation of this process is the system RANK / RANKL / OPG (osteoprotegerin), which provides a balance of activity of osteoblasts and osteoclasts. It blocks the interaction between RANK and RANKL by intercepting the RANKL ligand, which inhibits osteoclast development and reduces bone resorption. Thus, these properties of OPG can be considered as one of the pathogenetic factors in patients with dystrophic joint lesions.